<DOC>
	<DOCNO>NCT01438424</DOCNO>
	<brief_summary>The purpose study provide entecavir participant complete another entecavir trial without achieve virologic response relapse postdosing follow-up .</brief_summary>
	<brief_title>Safety Antiviral Activity Entecavir Participants With Chronic Hepatitis B Following Monotherapy Other Entecavir Trials</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Key inclusion criterion : Age 16 year old Receipt entecavir lamivudine previous entecavir study . Participants , base response entecavir : Virologic nonresponders Week 48 Partial virologic responder become nonresponders second year treatment Partial virologic responder Week 96 Complete responder relapse postdosing followup Decompensated liver disease AI463048 meet 1 follow criterion : Nonresponse adefovir least 24 week treatment Partial response adefovir 96 week treatment Complete response adefovir relapse postdosing followup Demonstrated intolerance adefovir Except participant enrol AI463048 , compensate liver disease . Key exclusion criterion : HIV coinfection Receiving nephrotoxic hepatotoxic agent Ongoing opportunistic infection Hemoglobin level &lt; 11.0 g/dL except enrolled AI463048 Platelet count &lt; 70,000 mm^3 except enrolled AI463048 Absolute granulocyte count &lt; 1,500 cells/mm^3 Recent history pancreatitis ( within 24 week prior first dose therapy ) Current evidence ascites require paracentesis , hepatic encephalopathy , variceal bleeding , except enrol AI463048 Known history allergy nucleoside analogue .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>